From the publishers of JADPRO

MPN Resource Center

Advertisement

A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Last Updated: Thursday, May 21, 2020

This phase 2, multicenter, double-blind trial analyzed the use of aspirin (100 mg aspirin once, twice [BID], or three times daily [TID]) for 2 weeks among 245 patients with essential thrombocythemia, as well as serum thromboxane B2 levels—a validated biomarker of COX-1 activity. Patients assigned to BID and TID dosing had lower median values (4 ng/mL and 2.5 ng/mL, respectively) compared with once daily dosing (19 ng/dL), leading to the conclusion that the antiplatelet response to low-dose aspirin can be improved with BID dosing. 

Blood
Advertisement
News & Literature Highlights
Advertisement
Advertisement